Multi-center, randomized, double-blind, placebo-controlled, cross-over Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)

开始日期2010-02-25

申办/合作机构

Revotar Biopharmaceuticals AG

EUCTR2009-013163-18-DE / Not yet recruitingN/A

A double-blind, placebo controlled, randomized, cross-over Phase IIa study to evaluate the effect of Bimosiamose on ozone induced sputum neutrophilia in healthy subjects.

开始日期2009-08-11

申办/合作机构

Revotar Biopharmaceuticals AG

EUCTR2008-000197-20-DE / Not yet recruitingN/A

Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis - Psoriasis POC

开始日期2008-11-28

申办/合作机构

Revotar Biopharmaceuticals AG

100 项与 Revotar Biopharmaceuticals AG 相关的临床结果

登录后查看更多信息

0 项与 Revotar Biopharmaceuticals AG 相关的专利（医药）

登录后查看更多信息

项与 Revotar Biopharmaceuticals AG 相关的文献（医药）

2010-01-01·Progress in Respiratory Research

Selectin antagonists and their potential impact for the treatment of inflammatory lung diseases

作者: Aydt, Ewald M. ; Wolff, Gerhard ; Bock, Daniel

A review.Selectin antagonists comprise a heterogeneous group of synthetic mols., natural product compounds and biologics.They are targeted against the selectin family of cell adhesion mols. (selectins), which are located on the surface of endothelial cells (E- and P-selectin), platelets (P-selectin) and of leukocytes (L-selectin).Selectins play a crucial role in the adhesion and activation of leukocytes and platelets in inflammation.They are supposed to be involved in the pathogenesis of several respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).Selectin antagonists targeting one, two or all three selectins (pan-selectin antagonists) were developed.Depending on the target binding site, sialyl Lewis X (sLe^X)-mimicking antagonists can be distinguished from antagonists mimicking more complex natural ligand structures like, for example, P-selectin glycoprotein ligand-1 (PSGL-1).To date, the most advanced pan-selectin antagonist in development is Bimosiamose mimicking both sLe^X and PSGL-1.It has been demonstrated to be effective in animal models of inflammatory lung diseases and human clin. trials for asthma and COPD.Based on the preclin. and clin. experiences with Bimosiamose, this chapter summarizes the potential impact of selectin antagonists for the treatment of inflammatory lung diseases.

2007-01-24·Journal of molecular modeling4区 · 化学

Density functional study of isoguanine tetrad and pentad sandwich complexes with alkali metal ions

4区 · 化学

Article

作者: Thomas Steinke ; Michael Meyer ; Jürgen Sühnel

Isoguanine tetraplexes and pentaplexes contain two or more stacked polyads with intercalating metal ions. We report here the results of a density functional study of sandwiched isoguanine tetrad and pentad complexes consisting of two polyads with Na(+), K(+) and Rb(+) ions at the B3LYP level. In comparison to single polyad metal ion complexes, there is a trend towards increased non-planarity of the polyads in the sandwich complexes. In general, the pentad sandwiches have relatively planar polyad structures, whereas the tetrad complexes contain highly non-planar polyad building blocks. As in other sandwich complexes and in metal ion complexes with single polyads, the metal ion-base interaction energy plays an essential role. In iG sandwich structures, this interaction energy is slightly larger than in the corresponding guanine sandwich complexes. Because the base-base interaction energy is even more increased in passing from guanine to isoguanine, the isoguanine sandwiches are thus far the only examples where the base-base interaction energy is larger than the base-metal ion interaction energy. Stacking interactions have been studied in smaller models consisting of two bases, retaining the geometry from the complete complex structures. From the data obtained at the B3LYP and BH&H levels and with Møller-Plesset perturbation theory, one can conclude that the B3LYP method overestimates the repulsion in stacked base dimers. For the complexes studied in this work, this is only of minor importance because the direct inter-tetrad or inter-pentad interaction is supplemented by a strong metal ion-base interaction. Using a microsolvation model, the metal ion preference K(+) approximately Rb(+) > Na(+) is found for tetrad complexes. On the other hand, for pentads the ordering is Rb(+) > K(+) > Na(+). In the latter case experimental data are available that agree with this prediction.

2006-08-01·Current Respiratory Medicine Reviews

The Role of Selectins During Lung Inflammation and Their Potential Impact for Innovative Therapeutic Strategies

作者: Wolff, Gerhard ; Aydt, Ewald M. ; Kuebler, Wolfgang M. ; Bock, Daniel

A review.The selectin family of cell adhesion mols. (selectins) is comprised of three structurally related calcium-dependent carbohydrate binding proteins, E-, P-, and L-selectin.Located on the surface of endothelial cells (E- and P-selectin), platelets (P-selectin) and of leukocytes (L-selectin), selectins are of vital importance for leukocyte recruitment and accumulation in the vasculature.Based on the unique architecture of the microvasculature of the lung, this task is achieved by two different types of selectin mediated functions (i) tethering and rolling of leukocytes on the pre- and post capillary pulmonary endothelium and in bronchial venules which are mediated by E-, P-, and L-selectin as well as (ii) retention of leukocytes in the pulmonary capillaries by L-selectin.Recent findings in preclin. and clin. research suggest a significant involvement of selectins in both acute and chronic inflammatory lung diseases such as acute lung injury (ALI), acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD) or idiopathic pulmonary fibrosis (IPF).This review summarizes the current progress in understanding the role of selectins during inflammation in the lung and its potential impact for innovative therapeutic strategies.

项与 Revotar Biopharmaceuticals AG 相关的新闻（医药）

2011-03-04

·BioSpace

Revotar Biopharmaceuticals Meets Primary Endpoint in Phase II COPD Study with Inhaled Bimosiamose

HENNIGSDORF, GERMANY--(Marketwire - March 04, 2011) - Revotar Biopharmaceuticals AG / Revotar Biopharmaceuticals meets primary endpoint in Phase II COPD Study with inhaled Bimosiamose Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement. BERLIN/Hennigsdorf (Germany), March 04, 2011 - Revotar Biopharmaceuticals AG today announced positive top-line results on a multi-center Phase II study to evaluate the safety and efficacy of inhaled Bimosiamose for the treatment of patients with chronic obstructive pulmonary disease (COPD). In a double-blind, placebo controlled, randomized, cross-over study, patients with moderate to severe COPD (GOLD II-III) inhaled Bimosiamose solution or vehicle for 28 consecutive days twice daily in two subsequent periods separated by a wash-out phase (cross-over). Cellular and non-cellular markers of induced sputum collected pre-/post treatment were analyzed. The study, conducted at 11 specialized centers in Germany, enrolled 77 patients. Inhalation of Bimosiamose was safe and well tolerated. Dose compliance recorded by the employed Akita(2) Apixneb nebulizer (Activaero) was high. On top of standard bronchodilator treatment, Bimosiamose showed a broad and favorable anti-inflammatory effect, reducing most of the evaluated sputum markers. In particular, Interleukin-8 (primary endpoint), a biomarker in COPD related to disease severity, was significantly reduced (p < 0.009) in sputum of Bimosiamose treated patients at day 28, as compared to placebo. Notably, there was a trend on improvement of lung function following inhalation with Bimosiamose. "This proof of concept study clearly demonstrates that inhaled Bimosiamose is attenuating inflammation in patients with COPD," said Prof Wolfgang Meyer- Sabellek, Chief Medical Officer of Revotar. "In addition, with trends in lung function improvement and a good safety pro data encourage to proceed with clinical development translating the anti-inflammatory potential of Bimosiamose into significant long-term clinical benefit." "This study is a major milestone on the way towards the establishment of pan- selectin antagonism as a novel therapeutic option in COPD", added Dr Martin Pöhlchen, CEO of Revotar. Detailed data will be submitted for publication in a peer-reviewed respiratory journal. About COPD Chronic Obstructive Pulmonary Disease (COPD) comprises several serious conditions affecting the lung. According to the WHO, COPD is affecting more than 210 million people worldwide, of which about 80 million people suffer from moderate to severe forms of the disease. More than 3 million people died of COPD in 2005, which corresponds to 5% of all deaths globally. The WHO predicts that COPD will become the third leading cause of death worldwide by 2030. In 2009, the global COPD market recorded sales of approximately 10 billion US-$. About Revotar Biopharmaceutical AG Revotar develops innovative drugs for inflammatory indications such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and asthma. Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in COPD, asthma, and psoriasis with a good safety and efficacy profile in over 300 patients and volunteers. Furthermore Revotar has two preclinical programs addressing respiratory and other inflammatory diseases. --- End of Message --- Revotar Biopharmaceuticals AG Neuendorfstr. 24a Hennigsdorf Germany Press Release (PDF): This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Revotar Biopharmaceuticals AG via Thomson Reuters ONE [HUG#1494541] Contact Address: Dr Martin Pohlchen, CEO Revotar Biopharmaceuticals AG Neuendorfstr. 24a D-16761 Hennigsdorf / Germany Phone: +49-3302-2025010 Fax: +49-3302-2025030 Email: Email Contact

合作创新药

100 项与 Revotar Biopharmaceuticals AG 相关的药物交易

登录后查看更多信息

100 项与 Revotar Biopharmaceuticals AG 相关的转化医学

登录后查看更多信息